US EditionPublished • loading... • Updated
BioVersys enters agreement with HMH to develop ansamycin - BioTuesdays
Summary by biotuesdays.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
BioVersys enters agreement with HMH to develop ansamycin - BioTuesdays
BioVersys (SIX: BIOV) has entered into an exclusive ansamycin drug discovery collaboration and license agreement with Hackensack Meridian Health (HMH), a U.S.-based private nonprofit health system, to jointly profile and develop ansamycin candidates. According to BioVersys, its proprietary Ansamycin Chemistry platform has been developed by research teams in France and Switzerland and has already produced several advanced, highly potent, orally b…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
